Jasper Therapeutics will host a webinar on January 8, 2025, to present preliminary BEACON study data on briquilimab.
Quiver AI Summary
Jasper Therapeutics, Inc., a biotechnology company focused on developing briquilimab, an antibody therapy aimed at treating mast cell driven diseases like chronic spontaneous urticaria (CSU) and asthma, announced a virtual webinar on January 8, 2025. This event will present preliminary data from their BEACON study on briquilimab's efficacy in CSU, with insights from Dr. Thomas B. Casale, a leading investigator in the study. Jasper is currently advancing briquilimab through clinical trials, where it has shown promising results in targeting the c-Kit receptor to deplete mast cells responsible for inflammatory responses. The press release also includes a cautionary note about forward-looking statements regarding the drug’s potential and clinical development risks.
Potential Positives
- Jasper Therapeutics will present preliminary data from the BEACON study of briquilimab, which could enhance the visibility and interest in their novel antibody therapy.
- The inclusion of Dr. Thomas B. Casale, a respected expert, in the webinar adds credibility and may attract more attention from the medical community and potential investors.
- Briquilimab has demonstrated an efficacy and safety profile in clinical studies, which supports its potential as a therapeutic option for chronic mast cell diseases.
Potential Negatives
- The announcement of a virtual webinar to present preliminary data may indicate that Jasper has not yet obtained conclusive results from its ongoing clinical studies, raising concerns about the readiness and completeness of its data.
- Jasper emphasizes numerous risks and uncertainties associated with its forward-looking statements, which may undermine investor confidence in the company's ability to fulfill its development and commercialization goals.
- The press release includes a long list of potential risks and conditions that could adversely affect the company's operations, which may give the impression of volatility and instability within the organization.
FAQ
What is the focus of Jasper Therapeutics?
Jasper Therapeutics specializes in developing briquilimab, an antibody therapy for mast cell driven diseases like chronic urticaria and asthma.
When is the upcoming webinar for the BEACON study?
The virtual webinar will take place on January 8, 2025, at 8:00 AM EST.
Who are the key speakers at the webinar?
Management and Thomas B. Casale, M.D., the lead US investigator of the BEACON study, will present at the webinar.
What diseases does briquilimab aim to treat?
Briquilimab is designed to treat chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
How can I register for the Jasper Therapeutics webinar?
Registration details for the webinar are available on the Jasper Therapeutics website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$JSPR Insider Trading Activity
$JSPR insiders have traded $JSPR stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $JSPR stock by insiders over the last 6 months:
- JEETINDER SINGH MAHAL (Chief Operating Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 1,800 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$JSPR Hedge Fund Activity
We have seen 46 institutional investors add shares of $JSPR stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVIDITY PARTNERS MANAGEMENT LP removed 782,000 shares (-100.0%) from their portfolio in Q3 2024
- BRAIDWELL LP added 483,300 shares (+inf%) to their portfolio in Q3 2024
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC added 350,000 shares (+inf%) to their portfolio in Q3 2024
- OCTAGON CAPITAL ADVISORS LP removed 287,500 shares (-100.0%) from their portfolio in Q3 2024
- SPHERA FUNDS MANAGEMENT LTD. removed 264,957 shares (-58.3%) from their portfolio in Q3 2024
- MORGAN STANLEY added 256,303 shares (+82.8%) to their portfolio in Q3 2024
- ALLY BRIDGE GROUP (NY) LLC added 180,852 shares (+82.7%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Jasper will host a virtual webinar on Wednesday, January 8, 2025, to present preliminary data from the BEACON study of briquilimab in CSU. In addition to management, the presentation will include remarks from Thomas B. Casale, M.D., Professor of Medicine and Pediatrics, University of South Florida Morsani College of Medicine, and lead US investigator in the BEACON study.
Registration details for the event are as follows:
Date:
Wednesday, January 8, 2025
Time:
8:00am EST
Registration:
Click Here
About Jasper
Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CIndU. For more information, please visit us at
www.jaspertx.com
.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; and Jasper’s timing for presenting preliminary data from the BEACON study. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:
Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com
Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertherapeutics.com
Lauren Walker (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
